View Older Stories View More Recent Stories

Apr 12, 2018 08:00AM Pfizer Doses First Patient Using Investigational Mini-Dystrophin Gene Therapy for the Treatment of Duchenne Muscular Dystrophy
Apr 10, 2018 02:01PM Pfizer (PFE) Says DMC Recommends Stopping Phase 3 Trial of Axitinib as Adjuvant Treatment for Patients at High Risk of RCC Recurrence After Surgery
Apr 10, 2018 02:00PM Pfizer Provides Update on Phase 3 Trial of Axitinib as Adjuvant Treatment for Patients at High Risk of Renal Cell Carcinoma Recurrence After Surgery
Apr 10, 2018 08:30AM Pfizer Signs Lease for the Spiral at Hudson Yards in Manhattan
Apr 9, 2018 08:00AM Allogene Therapeutics Completes Agreement for Pfizer’s Allogeneic CAR T Immuno-oncology Portfolio
Apr 9, 2018 08:00AM Pfizer Canada and MaRS Innovation Partner to Convert Great Science into Solutions to Benefit Canadians’ Health
Apr 4, 2018 08:01AM Pfizer (PFE) Says U.S. FDA and EMA Accept Regulatory Submissions for Review of Dacomitinib to Treat Metastatic NSCLC with EGFR-Activating Mutations
Apr 4, 2018 08:00AM U.S. FDA and European Medicines Agency Accept Regulatory Submissions for Review of Dacomitinib to Treat Metastatic Non-Small Cell Lung Cancer with EGFR-Activating Mutations
Apr 3, 2018 08:04AM Pfizer (PFE) and Allogene Therapeutics Enter Pact for Pfizer's Allogeneic CAR T Immuno-oncology Portfolio
Apr 3, 2018 08:00AM Pfizer and Allogene Therapeutics Enter into Asset Contribution Agreement for Pfizer’s Allogeneic CAR T Immuno-oncology Portfolio
Mar 29, 2018 12:46PM Pfizer (PFE) Reports Topline Results From Phase 3 ATTR-ACT Study Of Tafamidis to Treat Transthyretin Cardiomyopathy
Mar 29, 2018 12:45PM Pfizer Announces Positive Topline Results From Phase 3 ATTR-ACT Study Of Tafamidis In Patients With Transthyretin Cardiomyopathy
Mar 23, 2018 08:01AM Pfizer (PFE) Announces Top-Line Results from Study of CHANTIX/CHAMPIX (varenicline) in Adolescent Smokers
Mar 23, 2018 08:00AM Pfizer Reports Top-Line Results from a Study of CHANTIX®/CHAMPIX® (varenicline) in Adolescent Smokers
Mar 12, 2018 07:30AM Biogen to Acquire from Pfizer First-in-Class Phase 2b Ready Asset for Cognitive Impairment Associated with Schizophrenia
Mar 11, 2018 08:00AM Findings Released from Largest Real-World Data Analysis of Non-Valvular Atrial Fibrillation Patients Receiving Direct Oral Anticoagulants
Mar 8, 2018 04:52PM Pfizer (PFE) Confirms Favorable Outcome of FDA Panel Meeting on XELJANZ for Moderately to Severely Active UC
Mar 8, 2018 04:51PM Pfizer Announces Favorable Outcome of FDA Advisory Committee Meeting on XELJANZ® (tofacitinib) for Moderately to Severely Active Ulcerative Colitis
Mar 8, 2018 04:30PM Cellectis: Servier and Pfizer Announce Results of UCART19 First-in-Human Trials to Be Presented at the 44th EBMT (European Society for Blood and Marrow Transplantation) Annual Meeting
Mar 5, 2018 03:01PM Pfizer (PFE) Appoints Dan Littman to Board
Mar 5, 2018 03:00PM Dan R. Littman Elected to Pfizer’s Board of Directors
Feb 23, 2018 09:03AM Pfizer (PFE) Reports Positive CHMP Opinion for MYLOTARG & BOSULIF
Feb 23, 2018 09:00AM Pfizer Receives Positive CHMP Opinion for Two Hematology Medicines, MYLOTARG™ and BOSULIF®
Feb 23, 2018 08:33AM Pfizer (PFE) Reports Update on EMA Application for SUTENT (sunitinib)
Feb 23, 2018 08:30AM Pfizer Announces Update on European Marketing Authorization Application for SUTENT® (sunitinib) in Adult Patients at High Risk of Recurrent Renal Cell Carcinoma
Feb 23, 2018 08:09AM Pfizer (PFE) Announces Election of Albert Bourla, DVM, Ph.D. to Board
Feb 23, 2018 08:00AM Albert Bourla Elected to Pfizer’s Board of Directors
Feb 15, 2018 08:45AM Merck KGaA, Pfizer (PFE) Provide Update on Phase III JAVELIN Lung 200 Trial of Avelumab Monotherapy in Previously Treated Patients with Advanced NSCLC
Feb 15, 2018 08:30AM Merck KGaA, Darmstadt, Germany, and Pfizer Provide Update on Phase III JAVELIN Lung 200 Trial of Avelumab Monotherapy in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer
Feb 14, 2018 08:35AM Pfizer (PFE) Reports Breakthrough Therapy Designation from FDA for PF-04965842
Feb 14, 2018 08:30AM Pfizer Receives Breakthrough Therapy Designation from FDA for PF-04965842, an oral JAK1 Inhibitor, for the Treatment of Patients with Moderate-to-Severe Atopic Dermatitis
Feb 12, 2018 08:19AM Pfizer (PFE) Says U.S., EU and Japan Health Authorities Accept Regulatory Submissions for Review of its Third-Generation ALK Inhibitor Lorlatinib
Feb 12, 2018 08:00AM U.S., EU and Japan Health Authorities Accept Regulatory Submissions for Review of Pfizer’s Third-Generation ALK Inhibitor Lorlatinib
Feb 6, 2018 05:09AM NetVation DL Medicine Announces Research Collaboration with Pfizer Inc.
Feb 6, 2018 05:09AM NetVation DL Medicine Announces Research Collaboration with Pfizer Inc.
Jan 24, 2018 08:35AM Pfizer (PFE) Reports Positive Top-Line Results For Potential Biosimilar To Rituxan/MabThera
Jan 24, 2018 08:30AM Pfizer Announces Positive Top-Line Results For Potential Biosimilar To Rituxan®/MabThera®
Jan 16, 2018 07:05AM Foundation Medicine (FMI), Pfizer (PFE) Announce Pact to Develop Companion Diagnostics for Pfizer's Oncology Portfolio
Jan 16, 2018 07:00AM Foundation Medicine and Pfizer Announce Broad Partnership to Develop Companion Diagnostics for Pfizer’s Oncology Portfolio
Jan 8, 2018 08:24AM Pfizer (PFE) Announces New Partnership Model for Early-Stage Academic Research
Jan 8, 2018 08:00AM Pfizer Establishes New Partnering Model for Early-Stage Academic Research
Jan 3, 2018 07:32AM Sangamo Therapeutics (SGMO) and Pfizer (PFE) Announced Collaboration for ALS Treatments; $12M Upfront
Jan 3, 2018 07:31AM Sangamo and Pfizer announce collaboration for development of zinc finger protein gene therapy for ALS
Dec 22, 2017 07:02AM Merck (MRK) and Pfizer (PFE) Announce FDA Approval of SGLT2 Inhibitor STEGLATRO and Fixed-Dose Combination STEGLUJAN for Adults with Type 2 Diabetes
Dec 22, 2017 07:00AM FDA Approves SGLT2 Inhibitor STEGLATRO™ (ertugliflozin) and Fixed-Dose Combination STEGLUJAN™ (ertugliflozin and sitagliptin) for Adults with Type 2 Diabetes
Dec 21, 2017 01:10PM Merck (MRK) and Pfizer (PFE) Granted FDA Breakthrough Therapy Designation for Avelumab, INLYTA Combo in Advanced Renal Cell Carcinom
Dec 21, 2017 01:07PM FDA Grants Breakthrough Therapy Designation for Avelumab in Combination with INLYTA® in Advanced Renal Cell Carcinoma
Dec 21, 2017 01:00PM FDA Grants Breakthrough Therapy Designation for Avelumab in Combination with INLYTA® in Advanced Renal Cell Carcinoma
Dec 19, 2017 04:17PM Pfizer (PFE) Granted FDA Approves BOSULIF (bosutinib) for the Treatment of Patients with Newly-Diagnosed Ph+ Chronic Myelogenous Leukemia
Dec 19, 2017 04:11PM U.S. FDA Approves Pfizer’s BOSULIF® (bosutinib) for the Treatment of Patients with Newly-Diagnosed Ph+ Chronic Myelogenous Leukemia (CML)
View More Recent Stories View Older Stories